Gastroenterology and Hepatology Director:KAWASHIMA,Hiroki (Professor)

We proud to offer innovative prevention, diagnosis and treatment of digestive diseases. Our state-of-the-art technology enables early detection of gastrointestinal, liver, pancreas cancer and improves the life

We provide the highest quality patient care for a wide spectrum of diseases for the esophagus, stomach, small intestine, colon, rectum, liver, gallbladder, pancreas, and biliary tract.

Medical Care System

In the outpatient clinic, specialists of the gastrointestinal tract, biliary tract, pancreas, and liver provide medical care every day. Also, we perform screening tests such as upper and lower endoscopy and abdominal ultrasound every day. In the inpatient department, specialists provide medical care to inpatients as the attending physician.

Target Diseases

Benign diseases (e.g. reflux esophagitis, gastric ulcer, inflammatory bowel disease) and malignant diseases such as cancer of the gastrointestinal tract (esophagus, stomach, small intestine, and large intestine), acute / chronic hepatitis, liver cirrhosis, liver cancer, benign disease (bile duct / gallbladder stone and acute / chronic pancreatitis) and malignant disease such as cancer of the biliary tract and pancreas.

Strong Fields

We are actively involved in early detection and endoscopic therapy of gastrointestinal cancer. Also, we are confident in performing capsule endoscopy for small-bowel disease, diagnostic treatment using small intestinal endoscope, diagnostic treatment of viral hepatitis and liver cancer, ultrasonography for the biliary tract and pancreatic disease, and diagnostic treatment using endoscopes.

Clinical Results

We provide medical care to more than 200 patients with inflammatory disease a year. We perform endoscopic therapy in 250 or more patients with early gastrointestinal cancer a year; capsule endoscopy in 300 or more patients a year and small intestinal endoscopy in 400 or more patients a year; new interferon free therapy in 100 or more patients a year; and, perform diagnosis and treatment of biliary / pancreatic cancer in 40 or more patients a year.

Specialized Outpatient Clinic

Since two gastrointestinal tract specialists, two liver specialists, and one biliary tract and pancreas specialist provide medical care in the outpatient clinic every day, all patients will be examined by a specialist whenever they visit the clinic.

Advanced Medicine and Research

We recently identified Meflin as a specific marker of rCAFs in pancreatic cancer. Our studies revealed that rCAFs may represent proliferating resident fibroblasts. Using a pharmacological approach, we identified AM80, a synthetic unnatural retinoid, as a reagent that effectively converts Meflin-negative pCAFs to Meflin-positive rCAFs. We aimed to investigate the efficacy of a combination of AM80 and gemcitabine (GEM) andnab-paclitaxel (nab-PTX) in patients with advanced pancreatic cancer.
We conduct research on the diagnosis and treatment of early gastrointestinal cancer, polypectomy and balloon dilation using small intestinal endoscope.